title: Clinical course of choroidal neovascularization secondary to angioid streaks treated with intravitreal bevacizumab.
abstract: OBJECTIVE
  To evaluate visual acuity and anatomical outcomes of choroidal neovascularization (CNV) associated with angioid streaks after treatment with intravitreal bevacizumab injections.
  
  
  METHODS
  Best-corrected visual acuity, optical coherence tomography measurements (OCT), fluorescein and indocyanine green angiography, and ophthalmoscope examination at baseline and at each follow-up visit were performed. Five patients with CNV associated with angioid streaks were treated with injections of intravitreal bevacizumab (1.25 mg/0.05 mL). Re-treatment was recommended with symptomatic lesions, new subretinal hemorrhages, leakage on fluorescein and indocyanine green angiography, and/or fluid documented by OCT. Follow-up ranged between 18 and 32 months.
  
  
  RESULTS
  All eyes showed an improvement of visual acuity and were treated with at least four injections of intravitreal bevacizumab. Reduction of the leakage shown by fluorescein angiography and OCT was noted in all patients.
  
  
  CONCLUSIONS
  Intravitreal bevacizumab appears to be effective in stabilizing and recovering visual acuity in eyes with CNV associated with angioid streaks. Patients with early symptoms might benefit more.
authors.affiliation: Vision Institute Department of Ophthalmology, Universidade Federal de São Paulo (UNIFESP), São Paulo, Brazil. anderson.lbo@uol.com.br
authors.forename: Anderson
authors.initials: A
authors.lastname: Teixeira
authors.forename: Tessa
authors.initials: T
authors.lastname: Mattos
authors.forename: Roberta
authors.initials: R
authors.lastname: Velletri
authors.forename: Rafael
authors.initials: R
authors.lastname: Teixeira
authors.forename: Juliana
authors.initials: J
authors.lastname: Freire
authors.forename: Nilva
authors.initials: N
authors.lastname: Moares
authors.forename: Pedro Paulo
authors.initials: PP
authors.lastname: Bonomo
mesh_terms: D000328:Adult; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D000793:Angioid Streaks / Q000150:complications* / Q000188:drug therapy / Q000503:physiopathology; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D020256:Choroidal Neovascularization / Q000188:drug therapy* / Q000209:etiology* / Q000503:physiopathology; D004396:Coloring Agents; D005451:Fluorescein Angiography; D005500:Follow-Up Studies; D006801:Humans; D007208:Indocyanine Green; D058449:Intravitreal Injections; D008297:Male; D008875:Middle Aged; D019233:Retreatment; D041623:Tomography, Optical Coherence; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014792:Visual Acuity / Q000502:physiology; D055815:Young Adult
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D004396:Coloring Agents; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab; D007208:Indocyanine Green